<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of Experimental and Clinical Surgery</journal-id><journal-title-group><journal-title xml:lang="en">Journal of Experimental and Clinical Surgery</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник экспериментальной и клинической хирургии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2070-478X</issn><issn publication-format="electronic">2409-143X</issn><publisher><publisher-name xml:lang="en">Voronezh State Medical University named after N.N. Burdenko</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">227</article-id><article-id pub-id-type="doi">10.18499/2070-478X-2013-6-4-425-431</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Unknown</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Treatment of the Surgical Infection Caused Pseudomonas Aeruginosa in Experiment</article-title><trans-title-group xml:lang="ru"><trans-title>Специфический бактериофаг для лечения хирургической инфекции, вызванной Pseudomonas Aeruginosa, в эксперименте</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Козлова</surname><given-names>Ю.Н.</given-names></name><bio xml:lang="en"><p>Ph.D., Student of the Institute of Chemical Biology and Fundamental Medicine of the SB RAS</p></bio><bio xml:lang="ru"><p>аспирант Института химической биологии и фундаментальной медицины СО РАН</p></bio><email>author@vestnik-surgery.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Репин</surname><given-names>В.Е.</given-names></name><bio xml:lang="en"><p>Candidate of Biological Sciences, Senior Researcher of the Laboratory of Microbiology, Institute of Chemical Biology and Fundamental Medicine of the SB RAS</p></bio><bio xml:lang="ru"><p>к.б.н., зав. лабораторией микробиологии Института химической биологии и фундаментальной медицины СО РАН</p></bio><email>author@vestnik-surgery.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Майбородин</surname><given-names>И.В.</given-names></name><bio xml:lang="en"><p>MD, Professor, Senior Researcher of the Laboratory of Stem Cells, Institute of Chemical Biology and Fundamental Medicine of the SB RAS</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, ведущий научный сотрудник лаборатории стволовой клетки. Институт химической биологии и фундаментальной медицины СО РАН</p></bio><email>imai@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">The Institute of Chemical Biology and Fundamental Medicine, Russian Academy of Sciences, Siberian Branch, 8 Akademika&#13;
Lavrent'eva Ave., Novosibirsk, 630090, Russian Federation</institution></aff><aff><institution xml:lang="ru">Институт химической биологии и фундаментальной медицины СО РАН, Новосибирск, Российская Федерация</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2013-12-24" publication-format="electronic"><day>24</day><month>12</month><year>2013</year></pub-date><volume>6</volume><issue>4</issue><issue-title xml:lang="ru"/><fpage>425</fpage><lpage>431</lpage><history><date date-type="received" iso-8601-date="2016-04-27"><day>27</day><month>04</month><year>2016</year></date><date date-type="accepted" iso-8601-date="2016-04-27"><day>27</day><month>04</month><year>2016</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2013, Voronezh N.N. Burdenko State Medical University</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2013, ФГБОУ ВО ВГМУ им. Н.Н. Бурденко Минздрава России</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="en">Voronezh N.N. Burdenko State Medical University</copyright-holder><copyright-holder xml:lang="ru">ФГБОУ ВО ВГМУ им. Н.Н. Бурденко Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://vestnik-surgery.com/journal/about/editorialPolicies</ali:license_ref></license></permissions><self-uri xlink:href="https://vestnik-surgery.com/journal/article/view/227">https://vestnik-surgery.com/journal/article/view/227</self-uri><abstract xml:lang="en"><p>The purpose of the study By morphological methods to estimate results of specific bacteriophage use for treatment of the experimental pneumonia caused Pseudomonas Aeruginosa. Materials and methods The changes of rat lungs, liver and spleen after bacteriophage application for treatment of the pneumonia caused Pseudomonas Aeruginosa were studied by method of light microscopy. Results and their discussion It was revealed that specific phagetherapy leads to disappearance of signs of respiratory insufficiency, the general intoxication, the pneumonia and sepsis phenomena, the increase in survival rate of animals. However, in the lungs after treatment there were signs of formation of abscessis, in liver - dystrophic changes of hepatocytes, and in spleen - hypertrophy and hyperplasia of lymphoid nodules. These complications, which can as well as be pneumonia consequences and phage use, demand working out and application of specific measures of preventive maintenance and treatment. Conclusion Survival of animals as a result of only a phagetherapy of the acute septic pneumonia caused by Pseudomonas aeruginosa, without application of antibacterial drugs, even in the presence of various complications, certainly, is positive result. Further researches for specifica-tion of a dosage, ways of application, indications and contraindications, complications of bacteriophage use for treatment of surgical infections are required</p></abstract><trans-abstract xml:lang="ru"><p>Цель исследования Морфологическими методами исследовать результаты применения специфического фага для лечения у крыс экспериментальной пневмонии, вызванной синегнойной палочкой. Материал и методы Методом световой микроскопии изучали изменения легких, печени и селезенки крыс после применения бактериофага для лечения пневмонии, вызванной Pseudomonas Aeruginosa (синегнойная палочка). Результаты и их обсуждение Было обнаружено, что специфическая фаготерапия приводит к купированию признаков ды- хательной недостаточности, общей интоксикации, явлений пневмонии и сепсиса, увеличению выживаемости животных. Вместе с этим в легких после лечения имелись признаки абсцедирования, в печени - дистрофические изменения гепатоци- тов, а в селезенке - гипертрофия и гиперплазия лимфоидных узелков. Эти осложнения, которые могут как являться по- следствиями пневмонии, так и быть обусловлены использованием фага, требуют разработки и применения специфических мер профилактики и лечения. Заключение Сохранение жизни животных в результате только фаготерапии, без применения антибактериальных пре- паратов, острой септической пневмонии, вызванной Pseudomonas Aeruginosa, даже при наличии различных осложнений, является, безусловно, положительным результатом. Требуются дальнейшие исследования для уточнения дозировки, спо- собов применения показаний и противопоказаний, осложнений применения бактериофага для лечения хирургических ин- фекций.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Pseudomonas Aeruginosa, phagetherapy, pneumonia, sepsis, complications</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>Pseudomonas Aeruginosa, фаготерапия, пневмония, сепсис, осложнения</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1. Azzali G., Arcari M.L., Caldara G.F. "Rezhim"</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>ehkstravazacii limfocitov cherez VGE v PB</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>i ee rol' v normal'nyh samonavedeniya i vospalenie [The "mode" of</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>lymphocyte extravasation through HEV of Peyer's patches</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>and its role in normal homing and inflammation.] Microvasc.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Res. 2008; 75: 2: 227-237.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>2. Barrow P.A., Soothill J.S. Bakteriofag terapii i</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>profilaktika: vozrozhdenie i vozobnovlenie ocenku</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>potencial. [Bacteriophage therapy and</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>prophylaxis: rediscovery and renewed assessment of the</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>potential.] Trends Microbiol. 1997; 5: 7: 268-271.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>3. Kucharewicz-Krukowska A., Slopek S. Immunogennyj ehffekt</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>bakteriofaga u pacientov, podvergshihsya fagovoj terapii [Immunogenic effect</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>of bacteriophage in patients subjected to phage therapy.]</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Arch. Immunol. Ther. Exp. (Warsz). 1987; 35: 5: 553-561.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>4. Kutter E., Vos de D., Gvasalia G. et al. Fagovoj terapii v</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>klinicheskoj praktike: lechenie infekcij cheloveka [Phage therapy in</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>clinical practice: treatment of human infections.] Curr.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Pharm. Biotechnol. 2010; 1: 1: 69-86.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>5. Lederberg J. Men'she bloh ... do beskonechnosti: lechebnyj</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>bakteriofag perevozhd' [Smaller fleas ... ad infinitum: therapeutic</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>bacteriophage redux.] Proc. Natl. Acad. Sci. USA. 1996; 93:</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>8: 3167-3168.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>6. Levin B.R., Bull J.J. Populyacionnaya i ehvolyucionnaya dinamika</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>fagoterapii [Population and evolutionary dynamics</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>of phage therapy.] Nat. Rev. Microbiol. 2004; 2: 2: 166-173.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>7. Merril C.R., Biswas B., Carlton R. et al. Dlitel'no cirkuliruyushchih</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>bakteriofag v kachestve antibakterial'nyh agentov [Long-circulating</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>bacteriophage as antibacterial agents.] Proc. Natl. Acad.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Sci. USA. 1996; 93: 8: 3188-3192.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>8. O'Hanlon T.P., Lawless O.J., Katzin W.E. et al. Ogranichenie</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>i obobshchenie modeli TKR beta-cepi ehkspressii genov v</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>kapsuly implantata silikonovye grudi i udalennyh uchastkov tkani</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>vospalenie. [Restricted</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>and shared patterns of TCR beta-chain gene expression in</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>silicone breast implant capsules and remote sites of tissue</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>inflammation.] J. Autoimmun. 2000; 14: 4: 283-293.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>9. Pirnay J.P., Vos de D., Verbeken G. et al. V fagovoj terapii</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>paradigma: pret-a-porte ili syur-izmeryaem? [The phagetherapy</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>paradigm: prêt-à-porter or sur-mesure?] Pharm. Res. 2011;</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>28: 4: 934-937.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>10. Radetsky P. Vozvrashchenie horoshego virusa [Return of the Good Virus.] Discover. 1996; 17:</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>50-58.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>11. Slopek S., Durlakowa I., Weber-Dabrowska B. et al. Rezul'taty bakteriofaga dlya lecheniya gnojnyh bakterial'nyh</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>infekcij. I. Obshchaya ocenka rezul'tatov</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>[Results of bacteriophage treatment of suppurative bacterial</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>infections. I. General evaluation of the results.] Arch.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Immunol. Ther. Exp. (Warsz). 1983; 31: 3: 267-291.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>12. Slopek S., Kucharewicz-Krukowska A., Weber-Dabrowska</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>B., Dabrowski M. Rezul'taty bakteriofagovogo lecheniya</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>gnojnyh bakterial'nyh infekcij. 4. Ocenka</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>rezul'tatov, poluchennyh v 370 sluchayah [Results of bacteriophage treatment of</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>suppurative bacterial infections. IV. Evaluation of the</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>results obtained in 370 cases.] Arch. Immunol. Ther. Exp.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>(Warsz). 1985; 33: 2: 219-240.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>13. Slopek S., Weber-Dabrowska B., Dabrowski M.,</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Kucharewicz-Krukowska A. Rezul'taty bakteriofag</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>lechenie gnojnyh bakterial'nyh infekcij v gody</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>1981-1986 [Results of bacteriophage</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>treatment of suppurative bacterial infections in the years</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>1981-1986;] Arch. Immunol. Ther. Exp. (Warsz). 1987; 35:</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>5: 569-583.</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>14. Soothill J.S. Bakteriofag predotvrashchaet razrushenie kozhi</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>privivkoj ot sinegnojnoj palochki [Bacteriophage prevents destruction of skin</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>grafts by Pseudomonas aeruginosa.] Burns. 1994; 20: 3:</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>209-211.</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>15. Soothill J.S. Lechenie ehksperimental'nyh infekcij u myshej</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>s bakteriofagami [Treatment of experimental infections of mice</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>with bacteriophages.] J. Med. Microbiol. 1992; 37: 4: 258-</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>261.</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>16. Soothill J.S., Morton D.B., Ahmad A. V HID50</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>(pereohlazhdenie, vyzyvayushchee doza 50): al'ternativa LD50</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>dlya izmereniya bakterial'noj virulentnosti [The HID50</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>(hypothermia-inducing dose 50): an alternative to the LD50</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>for measurement of bacterial virulence.] Int. J. Exp. Pathol.</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>1992; 90: 2, 1992; 73: 1: 95-98.</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>17. Weber-Dabrowska B., Dabrowski M., Slopek S. Issledovaniya po</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>proniknovenie bakteriofaga u pacientov, podvergshihsya faga</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>terapiya [Studies on</mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation>bacteriophage penetration in patients subjected to phage</mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation>therapy.] Arch. Immunol. Ther. Exp. (Warsz). 1987; 35: 5:</mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation>563-568.</mixed-citation></ref></ref-list></back></article>
